Back to News
Market Impact: 0.2
Marker Therapeutics Secures $2.6 Mln FDA Grant To Support Phase 1 Of Pancreatic Cancer Study
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Marker Therapeutics was awarded $2.6 million by the FDA to support a Phase 1 clinical study of its investigational MAR-T cell therapy, MT-601. The article provides no clinical results or further details on the patient population in the available text.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
MRKR0.60
More News
- BlackRock, GIC among investors chasing Indian telecom major Jio's IPO as anchor bids top $26 billion
- Elice shares plunge 28% on debut as investor doubts over AI trade deepen
- Gartner analyst behind tech rout: AI returns are not yet large enough to justify neocloud build-out
- Walmart’s Flipkart is quietly building a food delivery challenger in India
- Credit stress is threatening to unwind the AI bull. All eyes are on Oracle to hold the line
- What Neoclouds Like CoreWeave Reveal About the Fragile AI Economy: Big Take Podc